Pembrolizumab (Keytruda)

Who we are

  • April 5, 2022
    Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
  • April 5, 2022
    Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer